State Street’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,157
| Closed | -$25.9K | – | 4376 |
|
|
2024
Q3 | $25.9K | Hold |
5,157
| – | – | ﹤0.01% | 4195 |
|
|
2024
Q2 | $34K | Buy |
5,157
+1,850
| +56% | +$12.6K | ﹤0.01% | 4212 |
|
|
2024
Q1 | $36.4K | Hold |
3,307
| – | – | ﹤0.01% | 4207 |
|
|
2023
Q4 | $44.6K | Hold |
3,307
| – | – | ﹤0.01% | 4214 |
|
|
2023
Q3 | $71.8K | Hold |
3,307
| – | – | ﹤0.01% | 4195 |
|
|
2023
Q2 | $127K | Buy |
3,307
+1,550
| +88% | +$54.7K | ﹤0.01% | 4151 |
|
|
2023
Q1 | $48.7K | Hold |
1,757
| – | – | ﹤0.01% | 4509 |
|
|
2022
Q4 | $57.9K | Hold |
1,757
| – | – | ﹤0.01% | 4528 |
|
|
2022
Q3 | $213K | Hold |
1,757
| – | – | ﹤0.01% | 4119 |
|
|
2022
Q2 | $308K | Hold |
1,757
| – | – | ﹤0.01% | 4020 |
|
|
2022
Q1 | $510K | Buy |
1,757
+1,343
| +324% | +$510K | ﹤0.01% | 4036 |
|
|
2021
Q4 | $216K | Sell |
414
-16
| -4% | -$11.5K | ﹤0.01% | 4316 |
|
|
2021
Q3 | $163K | Buy |
430
+22
| +5% | +$9.43K | ﹤0.01% | 4424 |
|
|
2021
Q2 | $365K | Buy |
408
+63
| +18% | +$48.2K | ﹤0.01% | 3979 |
|
|
2021
Q1 | $411K | Buy |
345
+215
| +165% | +$296K | ﹤0.01% | 3758 |
|
|
2020
Q4 | $172K | Buy |
130
+3
| +2% | +$4.4K | ﹤0.01% | 3768 |
|
|
2020
Q3 | $286K | Buy |
+127
| New | +$287K | ﹤0.01% | 3634 |
|
State Street's BIOR Position: Q4 2024 in Review
State Street sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 5,157 shares — an estimated $25.9K sold.
State Street first reported a position in BIOR in Q3 2020 and held it in 17 quarters. The position peaked at $510K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- State Street reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- State Street sold 5,157 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $25.9K.
- State Street first reported a position in Biora Therapeutics, Inc. Common Stock in Q3 2020 and held it in 17 quarters.
- State Street's Biora Therapeutics, Inc. Common Stock position peaked at $510K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on State Street's 13F filing for Q4 2024, filed 14 Feb 2025.